Chondroprotective drugs in degenerative joint diseases
نویسندگان
چکیده
منابع مشابه
Chondroprotective drugs in degenerative joint diseases.
Catabolic cytokine and anabolic growth factor pathways control destruction and repair in osteoarthritis (OA). A unidirectional TNF-alpha/IL-1-driven cytokine cascade disturbs the homeostasis of the extracellular matrix of articular cartilage in OA. Although chondrocytes in OA cartilage overexpress anabolic insulin-like growth factor (IGF) and its specific receptor (IGFRI) autocrine TNF-alpha re...
متن کاملRole of interleukin-7 in degenerative and inflammatory joint diseases
IL-7 is known foremost for its immunostimulatory capacities, including potent T cell-dependent catabolic effects on bone. In joint diseases like rheumatoid arthritis and osteoarthritis, IL-7, via immune activation, can induce joint destruction. Now it has been demonstrated that increased IL-7 levels are produced by human articular chondrocytes of older individuals and osteoarthritis patients. I...
متن کاملFeline degenerative joint disease.
OBJECTIVE To critically review and collate published information on feline degenerative joint disease (DJD) and identify areas in which information is lacking. STUDY DESIGN Critical literature review. METHODS Literature search through Pub Med, Commonwealth Agricultural Bureau Abstracts published in the English Language, or translated into English (January 1940-August 2008). RESULTS Althou...
متن کاملComparison of therapeutic efficacy of nimesulide and diclofenac in patients with degenerative joint diseases.
The efficacy and tolerability profiles of nimesulide and diclofenac were evaluated in 180 patients suffering from various degenerative joint diseases. The clinical evaluations were performed at 0, 2 and 4 weeks. Nimesulide (100 mg) tablets were administered twice daily and diclofenac (50 mg) tablets were administered thrice daily. The principal efficacy parameters were the improvement in pain a...
متن کاملAre We Using Slow-Acting Symptomatic Chondroprotective Drugs Conscious Enough?
BACKGROUND Osteochondral injuries constitute an entity that is widespread and can be seen in patients of all ages. Actual treatment modalities aim to relieve pain, obtain full range of movement of the joint, and improve the quality of life. There are many slow-acting chondroprotective agents prevalently used in the United States that are classified as nutritional support but not as medicines . ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rheumatology
سال: 2005
ISSN: 1462-0332,1462-0324
DOI: 10.1093/rheumatology/kei171